From Alzheimer’s disease research to the real-world setting: Connecting scientific progress with system readiness
During the AD/PD 2026 International Conference on Alzheimer’s and Parkinson’s Diseases, held in March in Copenhagen, Denmark, the focus was on the latest breakthroughs in treatment, translational research, early diagnosis, drug development, and clinical trials related to these neurodegenerative diseases (NDDs).
Following that conference, Lucid Strategy Consulting put together a new white paper – ‘Bridging the gap from scientific progress to system readiness in Alzheimer’s disease (AD)’ – as a consistent theme emerged across scientific and industry discussions: while progress in understanding NDDs has accelerated, the field is converging on the view that these diseases are biologically heterogeneous, with different progression trajectories, symptomatology, and lived experiences.
Ongoing trials reinforce the need for more precise patient characterisation and nuanced approaches to development. They also highlight a broader challenge: even as the field progresses, translating scientific advances into meaningful outcomes will require a deeper understanding of how these diseases are experienced and managed in real-world settings, not only by health systems, but also by patients and their families.
Lucid Strategy Consulting suggests three key themes for pharma strategists seeking market leadership in the AD space, including more integrated thinking across traditionally siloed functions and shifting from endpoint optimisation to holistic disease understanding, ensuring that clinical evidence meaningfully translates into practice.
In this white paper, discover how to build ecosystem partnerships that enable end-to-end care that aligns with the needs of patients, providers, and payers.
Find out how to embark on that journey here.
About Lucid
Lucid Group translates bold science into market impact, fused by scientific, strategic, commercial, creative, and human expertise, powered by our real-world data platform, to uncover the Lucid Truth: governing insights into what must shift for an asset to be adopted. Through bold, behavior-changing interventions, Lucid helps clients drive outstanding commercial performance and meaningful patient impact.
